| ALXO Stock | | | USD 1.74 0.11 6.75% |
This module uses fundamental data of Alx Oncology to approximate its Piotroski F score. Alx Oncology F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Alx Oncology Holdings. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Alx Oncology financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
Alx Oncology Altman Z Score,
Alx Oncology Correlation,
Alx Oncology Valuation, as well as analyze
Alx Oncology Alpha and Beta and
Alx Oncology Hype Analysis.
At this time, Alx Oncology's
Short and Long Term Debt Total is very stable compared to the past year. As of the 18th of January 2025,
Debt To Equity is likely to grow to 0.09, while
Net Debt is likely to drop (4.9
M). At this time, Alx Oncology's
Sales General And Administrative To Revenue is very stable compared to the past year. As of the 18th of January 2025,
Research And Ddevelopement To Revenue is likely to grow to 23.15, while
Book Value Per Share is likely to drop 3.25.
At this time, it appears that Alx Oncology's Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Unavailable
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | Lower Leverage| Focus | |
| Change In Outstending Shares | |
Alx Oncology Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Alx Oncology is to make sure Alx is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Alx Oncology's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Alx Oncology's financial numbers are properly reported.
Alx Oncology Holdings F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Alx Oncology's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Alx Oncology in a much-optimized way.
Click cells to compare fundamentals
About Alx Oncology Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
About Alx Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alx Oncology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alx Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Alx Oncology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
When determining whether Alx Oncology Holdings
offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock: Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share | Quarterly Revenue Growth | Return On Assets | Return On Equity |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine
if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.